A new rule from the Centers for Medicare and Medicaid Services in the US paves the way for critical access hospitals and rural hospitals to provide more outpatient and emergency treatment. The deployment of a new provider type, rural emergency hospitals, has begun with this.

A Condition of Participation for REHs can be used by small rural hospitals to request this provider status. This would enable them to continue offering emergency services, observation care, extra medical and outpatient services, as well as services for substance use disorders, behavioural health issues, and maternity health. The classification will allow rural hospitals to be paid for services rendered on or after January 1, 2023.

In the future proposed rules for the ambulatory surgical centre payment system and the outpatient prospective payment system for calendar year 2023, CMS anticipates more discussion on REHs with regard to topics like payment, Medicare enrollment, quality reporting, and more. The proposed regulation also contains a number of modifications for CAHs that provide services to rural populations.

In particular, CMS is recommending that the existing location and distance necessities, which are used to assess whether facilities qualify as CAHs, be amended to include a definition of major roadways. The proposed rule also includes recommendations that would permit CAHs that are a part of a bigger healthcare system (which may also include other hospitals and/or CAHs) to integrate and combine their programmes for infection control and prevention and antibiotic stewardship, quality assessment and performance improvement, and medical staff.

The establishment of a patient’s rights condition of participation is another proposal from CMS. This will provide CAHs with precise knowledge they may use to promote and safeguard patients’ rights. By August 29, stakeholders are urged to evaluate both proposed rules and, where appropriate, make formal comments. Later this year, when CMS creates its final, inclusive strategy for REHs, all feedback will be taken into account.

WHY THIS IS IMPORTANT

With a record-breaking 19 hospitals shutting in 2020 alone in the US, 138 rural hospitals have closed since 2010. Individuals living in rural areas are deprived of essential services, such as access to emergency care, when rural hospitals close. As per the Department of Health and Human Services, they predominately occur in areas with a higher percentage of people of colour and areas with higher rates of poverty.

In the United States, a fifth of the population lives in rural areas. According to HHS, health outcomes are lower in rural areas than in other communities due to shorter life expectancies, greater death rates, and a lack of local healthcare professionals.

According to CMS Administrator Chiquita Brooks-LaSure, the provision of the new rural emergency hospital provider type will preserve access to important health care services and help to eliminate inequities in rural regions. Health equity advancement, person-centered care innovation, and programme stability are all priorities for CMS. The action taken today to improve rural health advances their mission to guarantee that everyone served by these programmes has access to high-quality, reasonably priced healthcare.

THE GENERAL TEND

According to CMS, the new Medicare provider classification will let rural hospitals reduce the scope of their services without having to worry about closing. The Consolidated Appropriations Act of 2021 created the REH provider type to address the growing concern over rural hospital closures.

The rule advances efforts to retain access to healthcare in rural areas and reduce healthcare inequities. The capacity to retain doctors, nurses, and other professionals in rural areas is one factor. In tribal, rural, and urban populations that are underserved, there are more than 22,700 primary healthcare clinicians working.

Due to a new $1.5 billion commitment, which included $1 billion in supplementary American Rescue Plan financing and other mandated and yearly expenditures, HHS last year granted a record high number of health profession loan payback and scholarship initiatives.

The Vaccines and Related Biological Products Advisory Panel of the U.S. Food and Drug Administration gathered on June 30th to evaluate whether a change to the COVID-19 vaccine strain composition for booster doses for the fall and winter seasons of 2022 is required.

The COVID-19 vaccinations that the FDA has licenced for emergency use and approved have significantly improved public health and saved countless lives both domestically and abroad. But SARS-CoV-2, the virus that causes COVID-19, has undergone tremendous evolution, with current global outbreaks linked to the quick transmission of extremely contagious forms like omicron.

The most severe effects (hospitalisation and mortality) brought on by COVID-19 have been reduced thanks to currently available vaccines. However, post-authorization monitoring studies have reported that the efficacy of primary vaccination against several variations, particularly omicron, declines over time. Additionally, investigations have shown that the usefulness of initial booster dosages over time is fading, despite the fact that they initially restored resistance against severe illness and hospitalisation brought on by Omicron.

The American public can be confident that any COVID-19 vaccination that has received FDA authorization or approval satisfies the requirements for efficacy and safety. They urge everyone who is qualified to receive a booster to do so. To avoid the worst effects of COVID-19 as they head into the fall and winter, it is crucial that they have effective and safe vaccination boosters that can offer defence against existing and developing strains. The advisory group unanimously approved the inclusion of a SARS-CoV-2 omicron component in the COVID-19 vaccinations that would be used for boosters in the U.S. starting in the fall of 2022 after a comprehensive debate on June 28, 2022.

After the vote, and in an effort to use the best available evidence, they have advised manufacturers looking to update their COVID-19 vaccines to start creating modified vaccines by adding an omicron BA.4/5 spike protein element to the current vaccine structure to establish a two-component (bivalent) booster vaccine. This will allow the modified vaccines to possibly be used beginning in early to mid-fall 2022.

Since a principal series with the FDA-authorized and approved COVID-19 vaccines offers a basis of safeguard against serious outcomes of COVID-19 caused by circulating strains of SARS-CoV-2, they have not advised manufacturers to change the vaccine for primary vaccination as they anticipate this coming year to be a transition phase when this altered booster vaccine may be introduced.

Manufacturers of modified vaccines with an omicron BA.1 component have already submitted data from clinical studies, and they have instructed them to do so to the FDA for review before any prospective approval of a customised vaccination with an omicron BA.4/5 element. As the pandemic continues to evolve, manufacturers will also be urged to start clinical studies with modified vaccinations that have an omicron BA.4/5 component.

The FDA has been preparing for the potential need to modify vaccinations to address circulating variations and has already given advice to industry on how to do so successfully. The agency will assess all pertinent data to determine the safety, efficacy, and manufacturability of revised vaccines under review for authorisation or clearance to verify that they fulfil the FDA’s requirements, as it has done with all COVID-19 vaccines during the pandemic.

The FDA will share future plans about the prospective authorisation or clearance of COVID-19 vaccine booster doses with an omicron element as part of their commitment to transparency.

According to the European Medicines Agency and other international health agencies, coronavirus vaccinations that have been modified to incorporate the omicron variant strain can provide better protection when administered as a booster. Following a meeting on June 30th, the EMA said that international authorities had reached consensus on fundamental guidelines for revising COVID-19 injections to address new variations.

The researchers claimed that although the current coronavirus vaccinations continue to offer effective protection against hospitalisation and mortality, vaccine efficacy has decreased as the virus has changed. A bivalent or omicron-specific booster, which is a vaccine that contains both the new variety and the original coronavirus strain, could therefore improve and prolong protection, according to a statement from the EMA.

The mRNA vaccines are particularly mentioned in the statement. In order to include the omicron variety, Pfizer Inc. and Moderna Inc. have both been testing modified versions of their vaccines. According to the statement, booster doses of vaccines containing additional variants, such as the beta version, may be considered if clinical trial results show a sufficient level of neutralisation against the omicron and other dangerous forms. Omicron-specific boosters could reestablish defences against new coronavirus strains, according to advice from the World Health Organization.

However, it falls short of the stance taken by the American regulatory body, the Food and Drug Administration (FDA), which declared that it would specifically seek to include the more recent BA.4 and BA.5 strains of omicron, which are currently responsible for a rise in new infections across the globe, in any new vaccines intended for use domestically. The leader of a WHO advisory committee that has studied the modified shots said that the panel favoured boosters based on the BA.1 variant because it is more unique and may elicit a more widespread immune reaction than the more recently circulated subvariants.

According to top US FDA official Peter Marks, other nations’ authorities are seriously contemplating utilising new boosters based on the BA.1 omicron type that caused the dramatic increase in cases last winter because they may become accessible sooner than the BA.4/5-based booster the US intends to deploy. In the upcoming days, the EMA promised to release further information.

In an effort to shield last-mile communities from the pandemic, Amref Health Africa and AstraZeneca are introducing a fleet of Mobile Vaccination Clinics (MVCs) in partnership with the Ministry of Health (MoH) in Kenya. The ten mobile clinics will target hard-to-reach communities throughout Kenya with COVID-19 vaccinations and other health services.

The programme will boost Kenyans’ access to and use of vaccines. As of June 17, 2022, 31.4% of Kenya’s adult population had received the full COVID-19 immunisation, falling behind other world areas by 17.7%. When all 10 mobile clinics are fully operational, the daily vaccination target for each one will increase to 1,000 individuals.

By offering vaccine information, COVID-19 testing, convenient vaccination, and post-immunization care, the mobile clinics will aid in closing the COVID-19 vaccine gap. The custom-built clinics are run in collaboration with the County Health Departments and adhere to health and infection prevention control requirements. They are equipped with solar-powered refrigerators and a backup power supply. On-site web-enabled PCs make it easier to collect and report data on time. In order to ensure the mobile clinics’ efficient deployment, Amref Flying Doctors would restock them in difficult-to-reach locations.

It is obvious that health emergencies are going to stay, and thinking outside the box via innovations in health may be their only shot at prompt reaction if and when emergencies strike, stated Group CEO of Amref Health Africa, Dr. Githinji Gitahi. To prevent the harmful effects that health emergencies like COVID-19 have on communities, it is essential to address other health factors like non-communicable diseases that determine how health crises affect individuals. Therefore, the mobile clinics are a fantastic addition to the toolset that will guarantee equality of access to last-mile communities with crucial health services and much-needed vaccinations. They remain dedicated to maintaining the momentum toward immunising 70% of the eligible population through this creative solution, working with their partners, the Kenyan Ministry of Health, AstraZeneca, and other stakeholders in the commercial and governmental sectors. In the end, the clinics will strengthen the infrastructure of the healthcare system, enhancing the country’s readiness for medical catastrophes.

They are delighted to initiate this inventive collaboration with the Ministry of Health and Amref Health Africa to make sure that no Kenyan is left behind in their efforts to protect lives from COVID-19 and other life-threatening diseases, said Area Vice President, AstraZeneca for the Middle East and Africa, Dr. Pelin Incesu. This is a part of AstraZeneca’s continued dedication to a pandemic response that puts patients first. Their COVID-19 vaccine has already been distributed in more than three billion doses around the world, potentially saving 3.6 million lives.

The clinics will incorporate health promotion to make people aware of non-communicable diseases (NCDs) and provide continuity of NCD health services, focusing in particular on people with diabetes and hypertension. This will happen when Kenya incorporates immunisation services into primary health care. The clinics will assist current public health systems by acting as fixed clinics when they aren’t engaged in community outreach, easing the strain on nearby healthcare facilities.

According to Kaufman Hall’s most recent study, which is based on information from more than 900 institutions, U.S. hospitals and health systems continued to experience challenging financial and operational issues in May. The research states that profits are cumulatively negative almost halfway through 2022. While some indicators have returned to normal, hospitals are still performing below their pre-pandemic levels, and the outlook for the remainder of the year remains questionable.

The authors noted that hospitals continue to experience rising labour costs and declining labour hours as an indication of inflation and evidence that long-standing labour constraints are likely made worse by increased turnover.